1. Home
  2. Downgrades

Downgrades

MetLife-Spinoff Brighthouse Financial Impresses Analyst With Business Mix Improvements

Shares of Brighthouse Financial Inc (NASDAQ:BHF) remained highly volatile in early trading on Monday. The stock has lost 23% year to date on weaker capital generation and uncertainties around the ongoing free cash flow trends, according to Keefe, Bruyette & Woods. The Brighthouse Financial Analyst: Ryan Krueger upgraded the rating for Brighthouse Financial from Underperform […]

Huntington Bancshares Underperforming Relative To Peers, Analyst Downgrades Stock

Piper Sandler analyst R. Scott Siefers lowered Huntington Bancshares Incorporated (NASDAQ:HBAN) to Underweight from Neutral, lowering the price forecast to $11.5. According to Siefers, the stock is in for a period of underperformance following a stronger start to the year. Huntington Bancshares started the year on a solid note, highlighting a differentiated loan growth opportunity thanks to […]

These Cara Therapeutics Analysts Are No Longer Bullish: ‘We See No Obvious Future Value Drivers’

Shares of Cara Therapeutics Inc (NASDAQ:CARA) tanked in early trading on Thursday, with the Dow shedding more than 100 points. The company reported its quarterly results amid an exciting earnings season. Here are some key analyst takeaways. Needham analyst Joseph Stringer downgraded the rating on the stock from Buy to Hold. HC Wainwright analyst Oren […]

JP Morgan Downgrades Cleveland-Cliffs: Rising Capex And Modest Auto Demand Hamper Growth Prospects

Cleveland-Cliffs Inc. (NYSE:CLF) shares are trading lower after JP Morgan analyst Bill Peterson downgraded the stock from Overweight to Neutral and lowered the price target to $17 (from $23). The re-rating reflects reduced price forecasts for value-add and plate, rising capex needs through 2028, and limited near-term growth compared to industry peers. The analyst observes […]

This Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Bill Peterson downgraded the rating for Cleveland-Cliffs Inc. (NYSE:CLF) from Overweight to Neutral, while lowering the price target from $23 to […]

Tesla Crash Coming? Bearish Analyst Predicts 5% Stock Tumble If Musk’s Pay Plan Is Voted Down — But Sees A Silver Lining

A Tesla, Inc. (NASDAQ:TSLA) analyst predicts a potential 5% drop in the stock price if shareholders vote down CEO Elon Musk‘s controversial $56 billion pay package. What Happened: Toni Sacconaghi, an analyst at Bernstein with an “Underperform” rating on Tesla shares, believes passing the proposal will be difficult, Business Insider reported. “I think it’s going […]

Why Is AMD Stock Trading Lower On Monday?

Advanced Micro Devices Inc (NASDAQ:AMD) shares are trading lower after Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. The analyst noted AMD’s high valuations, highlighting the impact of Blackwell’s launch on Nvidia Corp’s (NASDAQ:NVDA) competitors. AMD appears costly compared to other large-cap AI companies like Nvidia and Broadcom Inc (NASDAQ:AVGO). Despite […]

Piper Sandler Maintains Underweight On Canopy Growth Stock, Calls Cannabis Rescheduling ‘Largely Symbolic’

A recent company note from Piper Sandler & Co, by senior analysts Michael S. Lavery and Luke Maloney offers insights into Canopy Growth Corporation‘s (NASDAQ: CGC) financial performance, valuation and prospects. The near-term outlook remains cautious, with significant valuation adjustments and an “Underweight” rating from Piper Sandler. Despite positive revenue trends amid economic challenges, investors should note […]

Ikena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It ‘Disappointing’

On Tuesday, Ikena Oncology Inc (NASDAQ:IKNA) discontinued the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhibitor, and continued clinical development of IK-595, a novel MEK-RAF molecular glue. Concurrently, Ikena is evaluating strategic options for the company and its development pipeline. The company said that based on a review of clinical data to date, available […]